Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: A prospective controlled study

Journal of the Medical Association of Thailand

Volumn 96, Issue 4, 2013, Pages 432-439

  Woratanarat, Khobchok ^a   Kanjanabuch, Talerngsak ^a   Suankratay, Chusana ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

AIDS; Fanconi syndrome; HIV; Nephrotoxicity; Tenofovir disoproxil fumarate; Thailand

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY FUNCTION TEST; KIDNEY TUBULE FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; TUBULAR DYSFUNCTION; URINE VOLUME;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; ZIDOVUDINE;

EID: 84876771951     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010; 17: 72-82.
2. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-78.
3. Tordato F, Cozzi LA, Cicconi P, De Luca A, Antinori A, Colangeli V, et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med 2011; 12: 4-13.
4. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. December 1, 2009 [cited 2010 Dec 8]. Available from: http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL001419.pdf.
6. Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, Leechawengwongs M, et al. The Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed 2010; 4: 515-28.
7. Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 2010; 78: 1060-3.
8. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and metaanalysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.
9. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9: 545-59.
10. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
11. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009; 23: 1971-5.
12. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-4.
13. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-3.
14. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-3.
15. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20: 641-8.
16. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734-40.
17. Bagga A, Bajpai A, Menon S. Approach to renal tubular disorders. Indian J Pediatr 2005; 72: 771-6.
18. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-96.
19. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010; 55: 78-81.
20. Mocroft A. The difficulties of classifying renal disease in HIV-infected patients. HIV Med 2011; 12: 1-3.
21. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78: 1171-7.
22. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviralnaive patients. AIDS 2008; 22: 2155-63.
23. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-304.
24. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-91.